Additional Octreotide Therapy to Sirolimus Achieved a Decrease in Sirolimus-refractory Chylous Effusion Complicated with Lymphangioleiomyomatosis

Recently, sirolimus, an inhibitor of mammalian target of rapamycin, was reported to decrease chylous effusion in patients with lymphangioleimyomatosis (LAM). We herein report a case of a 34-year-old woman with LAM who developed refractory chylothorax and chylous ascites during sirolimus therapy. In...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Intern Med
Autori principali: Namba, Masashi, Masuda, Takeshi, Nakamura, Takashi, Horimasu, Yasushi, Miyamoto, Shintaro, Nakashima, Taku, Iwamoto, Hiroshi, Fujitaka, Kazunori, Hamada, Hironobu, Hattori, Noboru
Natura: Artigo
Lingua:Inglês
Pubblicazione: The Japanese Society of Internal Medicine 2017
Soggetti:
Case Report
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5790722/
https://ncbi.nlm.nih.gov/pubmed/29021448
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.8645-16
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi